Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.47 |
| ▸ | F10 | P00742 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312982 | 0.86 | PTPN1 (0.35) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL24439949 | 0.82 | PTPN1 (0.43) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL9471834 | 0.79 | PTPN1 (0.43) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL14358370 | 0.79 | PTPN1 (0.46) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL31438077 | 0.79 | PTPN1 (0.43) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL678124 | 0.79 | PTPN1 (0.43) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL12547269 | 0.79 | PTPN1 (0.43) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL12547309 | 0.79 | HSD11B1 (0.45) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL336573 | 0.79 | PTPN1 (0.43) | PTPN1F10MMP2PTPN2CDC25B | |
| SCHEMBL13724016 | 0.79 | PTPN1 (0.46) | PTPN1F10MMP2PTPN2CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 954 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2025083496-A1 | COMPOSITIONS FOR SEBUM CONTROL | Dyson Operations PTE. LTD. (SG) | 2025-04-24 | — | — | WO | claimed |
| US-20250109503-A1 | MALEATED FATTY IMIDAZOLINE DERIVATIVES FOR CORROSION INHIBITORS | CHAMPIONX LLC (US) | 2025-04-03 | — | — | US | claimed |
| WO-2025071908-A1 | MALEATED FATTY IMIDAZOLINE DERIVATIVES FOR CORROSION INHIBITORS | CHAMPIONX LLC (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250099553-A1 | COMPOSITION AND METHODS FOR MODULATION OF ELOVL2 | YOUHEALTH BIOTECH, LIMITED (KY) | 2025-03-27 | — | — | US | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-20220409551-A1 | COMPOSITION COMPRISING POLAR LIPIDS AND METHOD OF MAKING SAME | Vaxa Technologies Ltd. (IL) | 2022-12-29 | — | — | US | claimed |
| EP-4101835-A1 | 18F-SUBSTITUTED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Blanchette Rockefeller Neurosciences Institute (US) | 2022-12-14 | — | — | EP | claimed |
| US-20220151973-A1 | HALOGENATED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Synaptogenix, Inc. (US) | 2022-05-19 | — | — | US | claimed |
| EP-3986387-A1 | COMPOSITION COMPRISING POLAR LIPIDS AND METHOD OF MAKING SAME | Vaxa Technologies Ltd. (IL) | 2022-04-27 | — | — | EP | claimed |
| WO-2014043625-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | BIND THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | WO | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| US-20110250183-A1 | Combination Therapy for Treatment of Patients with Neurological Disorders and Cerebral Infarction | MOLEAC PTE. LTD. (SG) | 2011-10-13 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| CN-1989093-A | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | EASTMAN KODAK CO (US) | 2007-06-27 | — | — | CN | claimed |
| US-7214834-B2 | Process for preparing enantiomerically pure 1,1′-spirobiindane-6,6′-diol derivatives | EASTMAN KODAK COMPANY (US) | 2007-05-08 | — | — | US | claimed |
| EP-1768943-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | EASTMAN KODAK COMPANY (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006019663-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | EASTMAN KODAK COMPANY (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060020150-A1 | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | EASTMAN KODAK COMPANY | 2006-01-26 | — | — | US | claimed |
| US-4039334-A | ORGANIC SILVER SALT AND HALIDE, REDUCING AGENT, ROSIN | FUJI PHOTO FILM CO., LTD. (JA) | 1977-08-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020150-A1 | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | HSD11B1, PKD1, REN | PTPN1 3068/4885F10 4482/4885MMP2 4126/4885 |
| US-20220409551-A1 | COMPOSITION COMPRISING POLAR LIPIDS AND METHOD OF MAKING SAME | PHOSPHO1, CNR2, ELOVL3 | PTPN1 4446/4885F10 3713/4885MMP2 4853/4885 |
| US-20250109503-A1 | MALEATED FATTY IMIDAZOLINE DERIVATIVES FOR CORROSION INHIBITORS | FASN, FFAR1, IGF1R | PTPN1 2858/4885F10 1015/4885MMP2 3951/4885 |
| US-20220151973-A1 | HALOGENATED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | PRKCH, PRKCA, PRKCD | PTPN1 4333/4885F10 4270/4885MMP2 4103/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | PTPN1 20/4885F10 3937/4885MMP2 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.